Amivantamab

Records for this ingredient, by country (identity only).

ATC L01FX18 · 13 markets · 38 records

Amivantamab 13 markets · 38 records Forms
Filters
MarketAU 7US 5GB 5CA 5ES 5MX 2TW 2JP 2SG 1CN 1HK 1EU 1FR 1
Kind

AU 7 records · 6 shown of 6 Source TGA、PBS Schedule API v3 (Department of +1 · Data as of 2026-10-28、live · some records have no stated strength · includes records with unknown status (not proof of sale)

Only this ingredient

  • 350 mg/7 mLinjectionRybrevant also in GB·JP·SG
    +1Other 1 marketsFR
  • 350 mg per mL / per unit basis not statedinjectionRYBREVANT amivantamab 350 mg/7 mL concentrate for solution for infusion vial unknown
  • 3,520 mg per mL / per unit basis not statedinjectionRYBREVANT SC amivantamab 1600mg/10mL solution for injection vial unknown
  • 2,400 mg per mL / per unit basis not statedinjectionRYBREVANT SC amivantamab 1600mg/10mL solution for injection vial unknown
  • 1,600 mg per mL / per unit basis not statedinjectionRYBREVANT SC amivantamab 1600mg/10mL solution for injection vial unknown
  • 2,240 mg per mL / per unit basis not statedinjectionRYBREVANT SC amivantamab 1600mg/10mL solution for injection vial unknown
1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
With a brand name Con nombre comercial 有商品名 有商品名Rybrevant ×2

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包

US 5 records · 5 shown of 5 Source openFDA NDC Directory · Data as of 2026-10-23

Only this ingredient

  • 350 mg per mL / per unit basis not statedinjectionRybrevant

Combination products containing this ingredient

  • 3,520 mg/22 mLinjection CombinationAmivantamab 3,520 mg/22 mL + Hyaluronidase (Human Recombinant) 44,000 mg/22 mLRybrevant Faspro
  • 2,400 mg/15 mLinjection CombinationAmivantamab 2,400 mg/15 mL + Hyaluronidase (Human Recombinant) 30,000 mg/15 mLRybrevant Faspro
  • 2,240 mg/14 mLinjection CombinationAmivantamab 2,240 mg/14 mL + Hyaluronidase (Human Recombinant) 28,000 mg/14 mLRybrevant Faspro
  • 1,600 mg/10 mLinjection CombinationAmivantamab 1,600 mg/10 mL + Hyaluronidase (Human Recombinant) 20,000 mg/10 mLRybrevant Faspro

GB 5 records · 5 shown of 5 Source NHSBSA dm+d · Data as of 2026-10-19

Only this ingredient

CA 5 records · 2 shown of 2 Source Health Canada Drug Product Databas · Data as of 2026-10-23

Only this ingredient

ES 5 records · 5 shown of 5 Source CIMA (AEMPS) · Data as of live

Only this ingredient

  • 3,520 mg per mL / per unit basis not statedinjectionRybrevant
  • 2,400 mg per mL / per unit basis not statedinjectionRybrevant
  • 1,600 mg per mL / per unit basis not statedinjectionRybrevant
  • 160 mg/1 mLinjectionRybrevant
  • 50 mg/1 mLinjectionRybrevant

MX 2 records · 0 shown of 0 Source COFEPRIS · Data as of annual · some records have no stated strength

2 records · 0 manufacturers 2 registros · 0 fabricantes 2 个记录 · 0 个厂家 2 個記錄 · 0 個廠商
With a brand name Con nombre comercial 有商品名 有商品名Rybrevant ×2Rybrevant Faspro ×2

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包

TW 2 records · 2 shown of 2 Source 衛生福利部食品藥物管理署（TFDA）全部藥品許可證資料集 · Data as of 2026-10-22

Only this ingredient

JP 2 records · 2 shown of 2 Source 厚生労働省 薬価基準収載品目リスト · Data as of 2026-11-01

Only this ingredient

  • 350 mg/7 mLinjectionライブリバント点滴静注350mg also in AU·GB·SG
    +1Other 1 marketsFR

Combination products containing this ingredient

  • 10 mL per mL / per unit basis not statedinjection CombinationAmivantamab 10 mL + Berahyaluronidase Alfa 10 mLリブロファズ配合皮下注

SG 1 records · 1 shown of 1 Source Health Sciences Authority (HSA) · Data as of 2026-08-07

Only this ingredient

CN 1 records · 1 shown of 1 Source 国家医保局 医保药品分类与代码数据库 · Data as of 2025-04-04

Only this ingredient

  • 350 mg per mL / per unit basis not statedinjection锐珂埃万妥单抗

HK 1 records · 0 shown of 0 Source 衞生署藥物辦公室（香港）註冊藥劑製品名單 · Data as of 2026-10-23 · some records have no stated strength · includes records with unknown status (not proof of sale)

1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
With a brand name Con nombre comercial 有商品名 有商品名RYBREVANT CONCENTRATE FOR SOLUTION FOR INFUSION 350MG/7ML ×1

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包

EU 1 records · 0 shown of 0 Source European Commission · Data as of 2026-11-03 · some records have no stated strength

EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.

1 records · 0 manufacturers 1 registros · 0 fabricantes 1 个记录 · 0 个厂家 1 個記錄 · 0 個廠商
With a brand name Con nombre comercial 有商品名 有商品名Rybrevant ×2

Full list in the data package Lista completa en el paquete de datos 完整清单见数据包 完整清單見資料包

FR 1 records · 1 shown of 1 Source Base de données publique des médic · Data as of 2026-11-03

Only this ingredient

  • 350 mg/7 mLinjectionRYBREVANT 350 mg, solution à diluer pour perfusion also in AU·GB·JP
    +1Other 1 marketsSG

Some strengths are recorded without a per mL / per unit basis. They are shown as recorded and are not compared with other markets.

The same ingredient can carry completely different brand names in different countries, and the same name can point to a different ingredient. Listed by country — not interchangeable.

Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.

A side-by-side table is offered only when this ingredient has records in many markets; otherwise this list is the whole picture.